Chat message

Slack / Private Message Drop, pp.105-106 [SLACK_000319] · slack_pm:msg:01073

Recipients on this medium are inferred from channel membership, not per-message addressing.

True - maybe Ad26 too (I don't know enough about that one). Ad5 does not seem appealing, although I'm pretty sure China will approve it (CanSino).

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

2020-07-23 09:02 Robert F. Garry open

Enough safety data should be there in the Phase I and II trials - you're right that the Moderna safety data is HIGHLY suspect.
2020-07-23 09:06 Kristian G. Andersen open

If I were a betting man, I'd put my money on ChAdOx1 and Sinovac - I'd forget anything RNA- or DNA-based for now- it's just too early for those platforms.
2020-07-23 09:08 Robert F. Garry open

"fully understand what they're signing up for" - lay it out for them - they might die. We've got a 1000 dying each day just in the US. Yes - some trial participants could die - I think it's less likely with the better treatment regiments -dexy, remdesivir if they get in trouble - give them Ho or Crowe's MAbs.
2020-07-23 09:10 Robert F. Garry open

AGree about the RNA/DNA - There are other vectors that could work too - even VSV- the devil we know....
2020-07-23 09:11 Kristian G. Andersen

True - maybe Ad26 too (I don't know enough about that one). Ad5 does not seem appealing, although I'm pretty sure China will approve it (CanSino).
2020-07-23 09:12 Robert F. Garry open

In my mind you definitely want the efficacy data first. If it doesn't work in young and health it won't work in the old and compromised.